Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million euros allotted to the development of new...
PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal...
PARIS, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal...
PARIS, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications...
PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly...
PARIS, May 09, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly...
PARIS, May 04, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly...
PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal...
Quantum Genomics has equipped itself with new financial means to pursue the development of firibastat and explore new therapeutic fields based on the patented technology platform built around...
Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription rightA minimum of €12 million subscription commitments...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.0721 | 0.0721 | 0.0721 | 0 | 0 | DE |
| 4 | 0 | 0 | 0.0721 | 0.0721 | 0.0721 | 0 | 0 | DE |
| 12 | -0.0051 | -6.60621761658 | 0.0772 | 0.0878 | 0.072 | 41278 | 0.07557478 | DE |
| 26 | -0.0393 | -35.2782764811 | 0.1114 | 0.138 | 0.001 | 781347 | 0.05107912 | DE |
| 52 | -0.0339 | -31.9811320755 | 0.106 | 0.155 | 0.001 | 429949 | 0.05729102 | DE |
| 156 | -4.2479 | -98.3310185185 | 4.32 | 4.498 | 0.001 | 314638 | 0.45164116 | DE |
| 260 | -3.4379 | -97.9458689459 | 3.51 | 6.185 | 0.001 | 312972 | 1.86062296 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
